NICE yes for NSCLC diagnostic tests could impact Iressa and Tarceva
This article was originally published in Scrip
Executive Summary
New guidance from NICE, the health technology appraisal institute for England and Wales, recommending EGFR-tyrosine kinase mutation tests for routine use on the National Health Service could improve the treatment of non-small cell lung cancer treatment. It could also impact use of Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), the two EGFR-TK inhibitors recommended by NICE to treat NSCLC.